English
Regional settings| Spread | 0.13 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 3.19 |
| Open | 3.31 |
| 1-Year Change | 28.79% |
| Day's Range | 3.29 - 3.31 |
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. It is also developing an integrated cataract treatment system, ALLY, which is designed to combine its existing femtosecond laser technology with phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.
BRIEF: For the fiscal year ended 31 December 2021, LENSAR Inc revenues increased 31% to $34.5M. Net loss decreased 1% to $19.6M. Revenues reflect Europe segment increase of 62% to $5.8M, South Korea segment increase of 42% to $4.4M. Lower net loss reflects Stock-based Compensation in SGA decrease of 21% to $5.9M (expense), Interest expense decrease from $1.3M (expense) to $0K.
